Hypoactive sexual desire and erectile dysfunction — compounds assessed
The 3 compounds the Institute assesses in hypoactive sexual desire and erectile dysfunction.
§4Compounds assessed
Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.
-
Change in Female Sexual Function Index desire domain of +0.30 versus +0.06 with placebo, and improvement in the Female Sexual Distress Scale item 13 of −0.73 versus −0.41 — Two identical phase 3 trials with statistically significant but small effects on…
Moderate -
Small randomised crossover studies in men with hypoactive sexual desire reported changes in limbic activation on functional imaging and in behavioural measures — Mechanistically interesting, clinically preliminary.
Low -
Non-selective melanocortin receptor agonist (cyclic heptapeptide)0 contributing trialsfull monograph
No adequately powered randomised trial identified for this compound — Development was discontinued. The approved compound in this family is its metabolite bremelanotide, and evidence for that compound does not transfer.
Very low
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health 2016;12(3):325–337. doi:10.2217/whe-2016-0018 · PMID 27638896
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.